{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057047","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.912493+00:00","generated_at":"2026-06-02T05:50:00.553286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tempest Q1 2024 net loss $7.9M ($0.36/sh); advancing TPST-1120 to pivotal Phase 3","bullets":["Cash $32.3M at March 31, 2024; expects runway into Q2 2025.","Net loss $7.9M ($0.36/sh) vs $7.6M ($0.55/sh) YoY; R&D $4.3M, G&A $3.6M.","TPST-1120 plans to advance to pivotal Phase 3 in first-line HCC, subject to FDA feedback.","TPST-1495 planned for Phase 2 in FAP in 2024 under NCI funding; updated data expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057047","json":"https://secwatch.observer/filing/0000950170-24-057047.json","markdown":"https://secwatch.observer/filing/0000950170-24-057047.md","text":"https://secwatch.observer/filing/0000950170-24-057047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/0000950170-24-057047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/tpst-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:50:00.553286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"738f66e41854ad6d573c970a6da4cd95b87212a4","claim":"Tempest Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $7.9 million, EPS $0.36.","evidence_excerpt":"Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/0000950170-24-057047-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$7.9 million"},{"label":"EPS","value":"$0.36"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}